| 000 | 01537 a2200421 4500 | ||
|---|---|---|---|
| 005 | 20250515015048.0 | ||
| 264 | 0 | _c20060510 | |
| 008 | 200605s 0 0 eng d | ||
| 022 | _a0007-1048 | ||
| 024 | 7 |
_a10.1111/j.1365-2141.2005.05948.x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJohnson, S A | |
| 245 | 0 | 0 |
_aGuidelines on the management of Waldenström macroglobulinaemia. _h[electronic resource] |
| 260 |
_bBritish journal of haematology _cMar 2006 |
||
| 300 |
_a683-97 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Practice Guideline; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xtherapeutic use |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Murine-Derived |
| 650 | 0 | 4 |
_aCladribine _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aEnzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 |
_aImmunosuppressive Agents _xtherapeutic use |
| 650 | 0 | 4 | _aPlasma Exchange |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aStem Cell Transplantation _xmethods |
| 650 | 0 | 4 |
_aThalidomide _xtherapeutic use |
| 650 | 0 | 4 |
_aVidarabine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aWaldenstrom Macroglobulinemia _xdrug therapy |
| 700 | 1 | _aBirchall, J | |
| 700 | 1 | _aLuckie, C | |
| 700 | 1 | _aOscier, D G | |
| 700 | 1 | _aOwen, R G | |
| 773 | 0 |
_tBritish journal of haematology _gvol. 132 _gno. 6 _gp. 683-97 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/j.1365-2141.2005.05948.x _zAvailable from publisher's website |
| 999 |
_c16098677 _d16098677 |
||